Novo Nordisk Pharma (Thailand) Ltd.

Industry and Activities


Senior Management

  1. John Christopher Dabwber, VP&GM
  2. Nanna Liborius Sjoerup, Financial & Operation Director
  3. Vera Bakirova, People & Organization Director
  4. Panpilai Chiramongkolporn, Legal & Compliance Director
  5. Nicolai A. Rhee, CMRQ Director
  6. Pitipong Payoongkitpaiboon, Commercial BU Director –Insulin
  7. Yuwadee Chiratiticharoen, Commercial BU Director – Obesity
  8. Ticha Chookham, Commercial BU Director – GLP-1

Contact Information
98, Sathorn Square Office Tower, Unit 2101-2105 21st Floor, North Sathorn Road, Silom Bangrak District, Bangkok 10500 Thailand
Phone Number:
+66 2 237 9263
Products and Services

We have been translating the unmet medical needs of people living with a serious chronic
disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today
are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine
We make long-term investments in novel treatments and technologies, including curative stem cellbased therapies, to continually advance the development of medical devices and digital health
Providing treatment for five diseases.
1. Diabetes Type 1
2. Diabetes Type 2
3. Obesity
4. Haemophilia
5. Growth Disorders

EABC Representative

John Christopher Dawber

Vice President & General Manager (Thailand)

Contact information for member only.

Company Profile

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic
diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering
scientific breakthroughs, expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and
markets its products in around 170 countries. For more information, visit,
Facebook, Twitter, LinkedIn and YouTube